Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALVNYSE:CSNASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVAutoliv$117.74-0.5%$104.38$75.49▼$118.34$9.10B1.37811,233 shs732,431 shsCSCredit Suisse Group$0.89$0.89$0.82▼$6.36$2.77B1.2737.84 million shsN/ATLXTelix Pharmaceuticals$16.12-2.3%$16.86$13.61▼$30.36$5.44BN/A28,587 shs31,814 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVAutoliv-0.31%+5.77%+14.63%+45.67%+8.51%CSCredit Suisse Group0.00%0.00%0.00%0.00%0.00%TLXTelix Pharmaceuticals-2.28%-1.68%-4.99%+18.47%+1,612,399,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVAutoliv4.0162 of 5 stars2.43.02.50.03.72.52.5CSCredit Suisse GroupN/AN/AN/AN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVAutoliv 2.81Moderate Buy$117.06-0.58% DownsideCSCredit Suisse Group 0.00N/AN/AN/ATLXTelix Pharmaceuticals 3.00Buy$22.3338.51% UpsideCurrent Analyst Ratings BreakdownLatest ALV, DAI, CS, and TLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.007/2/2025ALVAutolivJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$140.007/1/2025ALVAutolivWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$100.00 ➝ $104.006/25/2025ALVAutolivRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$133.006/12/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.006/5/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.005/28/2025ALVAutolivUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$103.00 ➝ $123.005/19/2025ALVAutolivWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$82.00 ➝ $100.005/16/2025ALVAutolivMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$95.00 ➝ $112.005/9/2025ALVAutolivBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/9/2025ALVAutolivBNP Paribas ExaneSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$123.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVAutoliv$10.39B0.88$13.58 per share8.67$29.40 per share4.00CSCredit Suisse Group$22.88B0.12$0.25 per share3.51$15.26 per share0.06TLXTelix Pharmaceuticals$516.72M10.56$0.11 per share140.73$1.12 per share14.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVAutoliv$647M$8.6913.5510.871.986.63%30.47%8.75%7/18/2025 (Estimated)CSCredit Suisse Group-$7.64B$0.651.37∞N/A15.12%23.83%1.81%N/ATLXTelix Pharmaceuticals$32.93MN/A0.0033.59N/AN/AN/AN/AN/ALatest ALV, DAI, CS, and TLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/18/2025Q2 2025ALVAutoliv$2.06N/AN/AN/A$2.57 billionN/A4/16/2025Q1 2025ALVAutoliv$1.72$2.15+$0.43$2.14$2.50 billion$2.58 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVAutoliv$2.802.38%N/A32.22%1 YearsCSCredit Suisse Group$0.055.62%N/A7.69%N/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ALatest ALV, DAI, CS, and TLX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/4/2025ALVAutolivquarterly$0.853.31%9/5/20259/5/20259/23/20255/8/2025ALVAutolivquarterly$0.702.9%5/21/20255/21/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVAutoliv0.660.970.73CSCredit Suisse Group2.791.531.53TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVAutoliv69.57%CSCredit Suisse Group11.20%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipALVAutoliv0.20%CSCredit Suisse GroupN/ATLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVAutoliv65,20077.31 million77.15 millionOptionableCSCredit Suisse Group50,4803.11 billionN/AOptionableTLXTelix PharmaceuticalsN/A338.38 millionN/AN/AALV, DAI, CS, and TLX HeadlinesRecent News About These CompaniesTelix Pharmaceuticals Stock Short Interest Report | NASDAQ:TLX - BenzingaJuly 3 at 5:30 PM | benzinga.comHC Wainwright & Co. Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Buy RecommendationJuly 3 at 5:30 PM | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What HappenedJuly 3 at 12:48 PM | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Coverage Initiated at HC WainwrightJuly 3 at 8:27 AM | marketbeat.comUp 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'June 30, 2025 | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?June 29, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What HappenedJune 27, 2025 | marketbeat.comTelix Pharmaceuticals Limited: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial DosesJune 25, 2025 | finanznachrichten.deTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?June 23, 2025 | marketbeat.comIlluccix Approved in U.S. for Patient Selection for Pre-Taxane RLTJune 23, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?June 20, 2025 | marketbeat.comTelix Precision Medicine Announces AlFluor Radiochemistry PlatformJune 20, 2025 | globenewswire.comTelix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025June 19, 2025 | globenewswire.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock Price Down 6.7% - Time to Sell?June 13, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares' (TLX) "Outperform" Rating Reaffirmed at WedbushJune 12, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Time to Sell?June 6, 2025 | marketbeat.comWilliam Blair Has Positive Estimate for TLX FY2025 EarningsJune 6, 2025 | marketbeat.comWedbush Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Outperform RecommendationJune 5, 2025 | msn.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's WhyJune 5, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Now Covered by WedbushJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Quantum Computing Inc. Is the Quiet Winner in Quantum StocksBy Jeffrey Neal Johnson | June 18, 2025View Why Quantum Computing Inc. Is the Quiet Winner in Quantum StocksMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure Boom3 Medical Technology Stocks Outperforming in 2025By Ryan Hasson | June 9, 2025View 3 Medical Technology Stocks Outperforming in 2025Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesALV, DAI, CS, and TLX Company DescriptionsAutoliv NYSE:ALV$117.74 -0.60 (-0.51%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$127.74 +10.00 (+8.49%) As of 07/3/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autoliv, Inc., through its subsidiaries, develops, manufactures, and supplies passive safety systems to the automotive industry in Europe, the Americas, China, Japan, and rest of Asia. It offers passive safety systems, including modules and components for frontal-impact airbag protection systems, side-impact airbag protection systems, seatbelts, steering wheels, and inflator technologies. The company also provides mobility safety solutions, such as pedestrian protection, battery cut-off switches, connected safety services, and safety solutions for riders of powered two wheelers. It primarily serves car manufacturers. Autoliv, Inc. was founded in 1953 and is headquartered in Stockholm, Sweden.Credit Suisse Group NYSE:CS$0.89 0.00 (0.00%) As of 06/13/2023Credit Suisse Group AG is a holding company, which engages in the provision of financial services. It operates through the following four divisions: Wealth Management, Investment Bank, Swiss Bank and Asset Management and four geographic regions: Switzerland, Europe, the Middle East and Africa (EMEA), Asia Pacific, and Americas. The Wealth Management division offers comprehensive wealth management and investment solutions, tailored financing, and advisory services to ultra-high-net-worth (UHNW) and high net-worth (HNW) individuals and external asset managers. The Investment Bank division offers a broad range of financial products and services focused on client-driven businesses and also supports Credit Suisse's Wealth Management division and its clients. The Swiss Bank division offers comprehensive advice and a wide range of financial solutions to private, corporate, and institutional clients in Switzerland. The Asset Management division offers investment solutions and services globally to a broad range of clients, including pension funds, governments, foundations and endowments, corporations, and individuals. The company was founded by Alfred Escher on July 5, 1856 and is headquaTelix Pharmaceuticals NASDAQ:TLX$16.12 -0.38 (-2.28%) As of 07/3/2025 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
